Carna Biosciences, Inc. Logo

Carna Biosciences, Inc.

Clinical-stage biopharma developing small molecule kinase inhibitors.

4572 | T

Overview

Corporate Details

ISIN(s):
JP3220550002
LEI:
Country:
Japan
Address:
神戸市中央区港島南町一丁目5番5号

Description

Carna Biosciences, Inc. is a clinical-stage biopharmaceutical company specializing in the discovery and development of small molecule kinase inhibitors. The company focuses on creating therapies for diseases with significant unmet medical needs, particularly in oncology and autoimmune disorders. Carna Biosciences operates through two core segments: a drug discovery business that advances its proprietary pipeline of drug candidates, and a drug discovery support business. The support division provides the global research community with a comprehensive portfolio of products and services, including a wide array of kinase proteins, biochemical and cell-based screening, and profiling services to accelerate pharmaceutical research and development.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-11 07:45
訂正有価証券届出書(組込方式)
Japanese 347.4 KB
2025-09-12 08:46
訂正有価証券届出書(組込方式)
Japanese 325.6 KB
2025-08-07 02:46
訂正有価証券届出書(組込方式)
Japanese 243.9 KB
2025-08-07 02:45
訂正有価証券届出書(組込方式)
Japanese 244.0 KB
2025-08-07 02:43
確認書
Japanese 8.8 KB
2025-08-07 02:42
半期報告書-第23期(2025/01/01-2025/12/31)
Japanese 358.3 KB
2025-07-11 08:47
有価証券届出書(組込方式)
Japanese 393.6 KB
2025-07-11 08:46
有価証券届出書(組込方式)
Japanese 393.6 KB
2025-07-11 08:45
有価証券届出書(組込方式)
Japanese 392.8 KB
2025-03-28 02:41
臨時報告書
Japanese 28.5 KB
2025-03-26 02:11
内部統制報告書-第22期(2024/01/01-2024/12/31)
Japanese 24.5 KB
2025-03-26 02:10
確認書
Japanese 8.7 KB
2025-03-26 02:08
有価証券報告書-第22期(2024/01/01-2024/12/31)
Japanese 1.3 MB
2024-09-25 08:39
臨時報告書
Japanese 122.5 KB
2024-08-08 02:51
確認書
Japanese 8.7 KB

Automate Your Workflow. Get a real-time feed of all Carna Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Carna Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Carna Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.